MedTrace Logo

Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery

NCT03850093 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2020-02-07

Study results available
· View outcomes & findings →

Summary

the current study hypothesized that Gabapentin can be effective as Bisoprolol in reduction of intraoperative bleeding, improving the operative's field visibility and increase the surgeon satisfaction via optimization of blood pressure and heart rate .

A prospective randomized double blinded controlled study. Eligible patients were randomized according to random list generated software and allocated into 3 equal and matched groups (15 patients in each group):-

* Group G: gabapentin group in which Patients were premedicated with oral gabapentin 1200 mg (Conventin 400mg; Evapharm) with sips of water, 2 hours before induction of anesthesia.
* Group B: bisoprolol group in which Patients were premedicated with oral bisoprolol 2.5 mg ( Concor 2.5mg ; Merck/Amoun ) with sips of water, 2 hours before induction of anesthesia.
* Group C: control group in which Patients were premedicated with oral placebo with sips of water, 2 hours before induction of anesthesia.

Conditions

  • Blood Pressure

Interventions

DRUG

Gabapentin1200 mg

patients received 1200mg gabapentin 2 hrs preoperative

DRUG

bisoprolol 2.5mg

patients received 2.5mg bisoprolol 2 hrs preoperative

DRUG

placebo

patients received oral placebo 2 hrs preoperative

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Abeer M. Elnakera, doctorate · faculty of medicine - Zagazig university

  • Ayman A. Hassan, doctorate · Zagazig University

  • Maram wagdy, Master · Zagazig University

  • Mohamed W. El-Anwar, doctorate · Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-10-31
Completion
2016-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850093 on ClinicalTrials.gov